SciELO - Scientific Electronic Library Online

 
vol.29 número4La molécula CD28 y su función en la activación de células TCaracterización clínica y de laboratorio del mieloma múltiple en el Instituto de Hematología e Inmunología índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Cubana de Hematología, Inmunología y Hemoterapia

versão impressa ISSN 0864-0289

Resumo

CABRERA-PAYNE, Yusselys et al. Evaluation of induction and consolidation classic treatment in de Novo acute non-lymphoblastic leukemia. Rev Cubana Hematol Inmunol Hemoter [online]. 2013, vol.29, n.4, pp. 368-381. ISSN 0864-0289.

Introduction: validation of cytogenetic and molecular abnormalities present at diagnosis is the most important prognostic factors of acute non-lymphoblastic leukemia. This has allowed us to establish the individual risk, stratify the patients and individualize their treatment. Objective: to describe the clinical behavior and outcome of patients with acute de novo non-lymphoblastic non-promyelocytic leukemia, receiving induction and classic consolidation therapy at the Department of Hematology of the Clinical Surgical Hospital «Hermanos Ameijeiras». Methods: a descriptive, prospective longitudinal study was carried out with 23 patients admitted between May 2008 and January 2011. Patients were stratified into: favorable, intermediate, poor risk groups, according to biological, molecular and cytogenetics clinical prognostic factors. Results: 60.9 % of patients had leukocyte counts less than 25 x 109/L, 47.8 % had myelomonocytic variant, 21.7 % had normal karyotype and 10% had translocation (8; 21). Mutations of the genes FLT3 and NPM1 were present in 2 and 3 patients respectively. 84 % of patients undergoing induction therapy achieved complete remission, predominantly the ones in the favorable risk group with no significant differences. In the favorable molecular risk group, the number of complete remissions was significantly higher (85.7 %) (p=0.05). The group of favorable risk patients remaining in complete remission with the consolidation treatment had 54.5 %, although it was not significant. Conclusions: the disease free survival was greater whereas overall survival rate was similar to the data reported in the international literature. Both were higher within the favorable risk group but without no significant difference, what is considered an important achievement of Cuban Healthcare System.

Palavras-chave : acute non-lymphoblastic leucemia; risk stratification; disease-free survival; overall survival.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License